Zolgensma hits the ground running, says Novartis

Zolgensma (onasemnogene abeparvovec) seems to have shrugged off the threat of payer resistance to its $2.1 million per one-shot treatment price tag, and an ongoing scandal over data manipulation at developer AveXis which was bought by Novartis for $8.7 billion.